Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Apr 24, 2019 · A total of 47 patients received tagraxofusp for the treatment of blastic plasmacytoid dendritic-cell neoplasm (BPDCN) as part of a four-stage, dose-escalation study.
Tagraxofusp - Wikipedia
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). [5] [6] Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.
BPDCN Treatment | ELZONRIS® (tagraxofusp-erzs)
ELZONRIS ® (tagraxofusp-erzs) is the only approved treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Tagraxofusp Uses, Side Effects & Warnings - Drugs.com
Jul 22, 2024 · What is tagraxofusp? Tagraxofusp is used to treat blastic plasmacytoid dendritic cell neoplasm, a rare blood and/or bone marrow cancer. tagraxofusp is for use in adults and children at least 2 years old. Tagraxofusp may also be used for purposes not listed in this medication guide.
Tagraxofusp, the first CD123-targeted therapy and first targeted ...
Tagraxofusp is an intravenously administered CD123-directed cytotoxin consisting of the fusion of interleukin-3 with a truncated diphtheria toxin payload and was recently approved by the Food and Drug Administration for the treatment of adults and children aged 2 and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm: a 2 …
Nov 20, 2023 · As recently as 1 September 2023, tagraxofusp has been designated by the Ministry of Health, Labour and Welfare of Japan as an orphan drug for BPDCN. The orphan drug designation is intended for therapeutic use in <50 000 …
FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell
On December 21, 2018, the Food and Drug Administration approved tagraxofusp-erzs (ELZONRIS, Stemline Therapeutics), a CD123-directed cytotoxin, for blastic plasmacytoid dendritic cell neoplasm...
Elzonris | European Medicines Agency (EMA)
Jul 24, 2020 · The active substance in Elzonris, tagraxofusp, is made up of diphtheria toxin (a substance which is poisonous to cells), linked to a protein called interleukin 3. The interleukin-3 portion of the medicine attaches to receptors (targets) which are found in …
Tagraxofusp-erzs - NCI - National Cancer Institute
Tagraxofusp-erzs is approved to treat: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in children aged 2 years and older. Tagraxofusp-erzs is also being studied in the treatment of other types of cancer.
Tagraxofusp-erzs (intravenous route) - Mayo Clinic
Jan 31, 2024 · Tagraxofusp-erzs injection is used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). This medicine is to be given only by or under the direct supervision of your doctor.